Top Story

Bioventus extends distribution agreement of HA treatment for OA

July 24, 2016

Bioventus announced in a press release that it has entered into an agreement with the Seikagaku Corporation to extend distribution of Supartz FX in the United States.

According to the release, the original distribution agreement for the hyaluronic acid (HA) injection used to treat knee osteoarthritis expires on May 2017. Under the extension, Bioventus will continue to distribute Supartz FX in the United States through May 2019.

Several factors associated with time to clinical union following ankle fracture

July 23, 2016
TORONTO — Tibiotalar dislocation, BMI, external fixation for initial stabilization and delay of definitive management significantly correlated with time to…
In the Journals

Female physicians make 'substantially' less than male counterparts

July 22, 2016
Significant salary differences exist between male and female physicians at public medical schools, according to findings published in JAMA Internal Medicine. This gap…

Higher ASA class, BMI associated with decreased physical function after ankle surgery

July 22, 2016
TORONTO — Increased American Society of Anesthesiologists class, BMI and patient age at the time of surgery for ankle fracture were independently predictive of…

Nearly half of physicians see fewer patients each day due to EHR use

July 22, 2016
Physicians have mixed feelings about electronic health record usage, according to a report published by Physicians Practice. The 2016 Tech Report included an annual…
More News Headlines »